Omrix Biopharmaceuticals, Inc., a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that Nissim Mashiach, President & Chief Operating Officer, is scheduled to give a company presentation at the Rodman & Renshaw Annual Healthcare Conference on Monday, November 10, 2008 at 2:25 p.m. ET at the New York Palace Hotel in New York City.

A live webcast of the presentation will be available on the Company’s corporate web site at www.omrix.com. Participants are urged to log on to the web site 15 minutes prior to the scheduled start time to download and install any necessary audio software. A replay of the webcast will begin shortly after the live presentation time and will be available for 90 days.

About Omrix Biopharmaceuticals, Inc.

Omrix is a fully integrated biopharmaceutical company that develops, manufactures and markets protein-based biosurgery and passive immunotherapy products. Omrix’ biosurgery product line includes products and product candidates that are used for the control of bleeding, or hemostasis, and other surgical applications. The Company’s passive immunotherapy product line includes antibody-rich products and product candidates for the treatment of immune deficiencies, infectious diseases and potential biodefense applications.

Safe Harbor Statement

This news release contains forward-looking statements. Forward-looking statements provide the Company’s current expectations or forecasts of future events. Forward-looking statements include statements about the Company’s expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. The Company’s actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the Company’s filings with the Securities and Exchange Commission (SEC), including sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form 10-K as filed with the SEC on March 17, 2008, and the Company’s most recent quarterly reports on Form 10-Q and its current reports on Form 8-K. Unless required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect circumstances or events after the date of this news release.

This entry was posted on Tuesday, November 4th, 2008 at 1:10 pm and is filed under Health care. Tags: antibody-rich products, biopharmaceutical, biosurgical and immunotherapy, biosurgical and immunotherapy products, corporate web site, immunotherapy, immunotherapy products, Inc., infectious diseases, New York, New York City, New York Palace Hotel, Nissim Mashiach, Omrix Biopharmaceuticals, passive immunotherapy, potential biodefense applications, Rodman & Renshaw, Rodman & Renshaw Capital Group, Securities and Exchange Commission, surgical applications, treatment of immune deficiencies, United States. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.